Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDR2 | Q16832 | 2/20 | 0.51 |
| ▸ | NAMPT | P43490 | 6/20 | 0.43 |
| ▸ | KCNQ3 | O43525 | 2/20 | 0.42 |
| ▸ | KCNQ2 | O43526 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | KDR | P35968 | 3/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | BRAF | P15056 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL171046 | 0.92 | DDR2 (0.62) | DDR2NAMPTKCNQ3KCNQ2MAPK1 | |
| SCHEMBL16990615 | 0.90 | DDR2 (0.51) | DDR2NAMPTMAPK1KDRNPC1 | |
| SCHEMBL15574271 | 0.89 | NAMPT (0.48) | NAMPTKDRNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL13603587 | 0.82 | DDR2 (0.59) | DDR2MAPK1KDRBRAFSMN1; SMN2 | |
| SCHEMBL15574415 | 0.82 | DDR2 (0.62) | DDR2MAPK1KDRBRAFMEN1 | |
| SCHEMBL15573040 | 0.80 | KDR (0.56) | DDR2MAPK1KDRBRAFMEN1 | |
| SCHEMBL16990729 | 0.80 | CA2 (0.52) | NAMPTKDRMEN1KMT2A | |
| SCHEMBL15573117 | 0.79 | DDR2 (0.56) | DDR2NPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL16990593 | 0.79 | DDR2 (0.58) | DDR2MEN1KMT2A | |
| SCHEMBL16990725 | 0.79 | DDR2 (0.56) | DDR2MAPK1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150225369-A1 | DDR2 INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS | MERCK PATENT GMBH (DE) | 2015-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150225369-A1 | DDR2 INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS | DDR2, DDR1, DDRGK1 | DDR2 1/4885NAMPT 2021/4885KCNQ3 4654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.